High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition

Yulei Gu1,2*, Chao Li3*, Lili Xiao1, Juan Li1, Hui Pei2, Dong Xu1, Yumin Jiang1, Xiaofan Zhang1, Luanluan Zhang1, Kongfei Li4, Zhiqiang Zhu2, Xiaolong Chen1

1Key Laboratory of Clinical Medicine, 2Emergency Intensive Care Unit, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052; Henan Province, China; 3Department of Orthopaedic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, 127 Dongming Road, Zhengzhou 450008, Henan Province, China; 4Department of Hematology, Yinzhou People’s Hospital Affiliated to Medical College of Ningbo University, Ningbo, Zhejiang Province, China. *Equal contributors.

Received April 20, 2019; Accepted August 22, 2019; Epub September 15, 2019; Published September 30, 2019

Abstract: Background: Cholangiocarcinoma (CCA) is a biliary malignancy, which is notoriously difficult to diagnose and associated with poor survival. Accumulating evidence indicates that long non-coding RNA Nicotinamide Nucleotide Transhydrogenase-antisense RNA1 (NNT-AS1) is overexpressed in several tumors and plays a crucial role in the development of neoplasm. However, the expression pattern and functional role of NNT-AS1 in CCA remain largely unknown. Methods: NNT-AS1 expression was assessed by RT-qPCR and In Situ Hybridization (ISH) assay. The clinical relevance of NNT-AS1 was analyzed using a CCA tissue microarray with follow-up data. The function role of NNT-AS1 and its underlying molecular mechanisms were evaluated using both in vitro/in vivo experiments and bioinformatics analysis. Luciferase reporter assay, western blot and RT-qPCR were conducted to identify the miRNA/target gene involved in the regulation of CCA progression. Results: LncRNA NNT-AS1 was found highly expressed in CCA. Upregulated NNT-AS1 expression was tightly associated with clinical malignancies and predicted poor prognosis of CCA patients. Functional studies showed that NNT-AS1 knockdown inhibited cell proliferation, migration and invasion of CCA cells in vitro. Conversely, NNT-AS1 overexpression showed the opposite biological effects. In a tumor xenograft model, we confirmed that NNT-AS1 knockdown could significantly inhibit the growth of CCA, while NNT-AS1 overexpression promoted CCA development. Mechanistically, we demonstrated that NNT-AS1 might function as a ceRNA in regulating HMGA2 (high mobility group AT-hook 2) through competitively binding to miR-142-5p in CCA. Moreover, we showed that NNT-AS1 regulated epithelial-mesenchymal transition in CCA. Conclusion: In summary, these findings suggest the potential prognostic and therapeutic value of NNT-AS1/miR-142-5p/HMGA2 axis in CCA patients.

Keywords: NNT-AS1, cholangiocarcinoma, proliferation, tumor progression, epithelial-mesenchymal transition

Introduction

Cholangiocarcinoma (CCA) is the second most common neoplasm arising in intrahepatic, peripheral, and extrahepatic biliary tree. Its incidence has significantly increased in recent decades worldwide [1]. Most patients are diagnosed with advanced stages which are not suitable to potentially curative surgical therapies [2]. To date, patients with CCA have poor survival despite treatment with chemotherapy. Dismal clinical outcome of CCA is due to, at least in part, aggressive biologic behaviors and high rate of tumor recurrence [3]. Thus, further elucidation of the underlying molecular mechanism of CCA is an important step toward developing more novel and effective biomarker and treatment strategies.

Long non-coding RNAs (lncRNAs) are a new class of noncoding RNA molecules over than 200 nt [4]. Over the past decade, mounting evidence has demonstrated that lncRNAs play critical roles in human diverse biological processes [5]. Additional, lncRNA dysregulation has been documented to contribute to neoplasm initiation, development and metastasis [6]. For example, AFAP1-AS1 was reported significantly overexpressed in CCA and promoted tumor progression through regulating the
NNT-AS1 promotes cholangiocarcinoma progression

Table 1. Correlation of clinico-pathological features with NNT-AS1 expression in CCA TMA cohort

<table>
<thead>
<tr>
<th>Clinicopathological variables features</th>
<th>NNT-AS1 expression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low expression</td>
<td>High expression</td>
</tr>
<tr>
<td></td>
<td>(n=42)</td>
<td>(n=47)</td>
</tr>
<tr>
<td>Age (years) ≤55</td>
<td>22 (52.4)</td>
<td>21 (44.7)</td>
</tr>
<tr>
<td>&gt;55</td>
<td>20 (47.6)</td>
<td>26 (55.3)</td>
</tr>
<tr>
<td>Gender Male</td>
<td>25 (59.5)</td>
<td>24 (51.1)</td>
</tr>
<tr>
<td>Female</td>
<td>17 (40.5)</td>
<td>23 (48.9)</td>
</tr>
<tr>
<td>Liver Cirrhosis NO</td>
<td>15 (35.7)</td>
<td>16 (34.0)</td>
</tr>
<tr>
<td>YES</td>
<td>27 (64.3)</td>
<td>31 (66.0)</td>
</tr>
<tr>
<td>TNM stage Stage I/II</td>
<td>29 (69.0)</td>
<td>20 (42.6)</td>
</tr>
<tr>
<td>Stage III</td>
<td>13 (31.0)</td>
<td>27 (57.4)</td>
</tr>
<tr>
<td>Tumor size (cm) ≤5</td>
<td>26 (61.9)</td>
<td>28 (59.6)</td>
</tr>
<tr>
<td>&gt;5</td>
<td>16 (38.1)</td>
<td>19 (40.4)</td>
</tr>
<tr>
<td>Intrahepatic metastasis No</td>
<td>28 (66.7)</td>
<td>21 (44.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>14 (33.3)</td>
<td>26 (55.3)</td>
</tr>
<tr>
<td>Vascular invasion Absent</td>
<td>26 (61.9)</td>
<td>15 (31.9)</td>
</tr>
<tr>
<td>Present</td>
<td>16 (38.1)</td>
<td>32 (68.1)</td>
</tr>
<tr>
<td>Tumor multiplicity Single</td>
<td>27 (64.3)</td>
<td>24 (51.1)</td>
</tr>
<tr>
<td>Multiple</td>
<td>15 (35.7)</td>
<td>23 (48.9)</td>
</tr>
<tr>
<td>Tumor envelope No</td>
<td>32 (76.2)</td>
<td>30 (63.8)</td>
</tr>
<tr>
<td>Yes</td>
<td>10 (23.8)</td>
<td>17 (36.2)</td>
</tr>
<tr>
<td>HBsAg No</td>
<td>30 (71.4)</td>
<td>29 (61.7)</td>
</tr>
<tr>
<td>Yes</td>
<td>12 (28.6)</td>
<td>18 (38.3)</td>
</tr>
<tr>
<td>Survival status Live</td>
<td>34 (81.0)</td>
<td>23 (48.9)</td>
</tr>
<tr>
<td>Dead</td>
<td>8 (19.0)</td>
<td>24 (51.1)</td>
</tr>
</tbody>
</table>

Herein, we investigated the expression profile of lncRNA NNT-AS1 and further explored its biological function in CCA. We found that NNT-AS1 was markedly overexpressed in CCA. High level of NNT-AS1 expression was associated with poor prognosis and clinical malignancies in CCA patients. NNT-AS1 knockdown impaired cell proliferation and invasion abilities. Meanwhile, silencing NNT-AS1 inhibited the tumor growth in a CCA xenograft tumors model. Mechanistically, we demonstrated that NNT-AS1 might function as a ceRNA in regulating HMGA2 through competitively binding to miR-142-5p in CCA. Moreover, we showed that NNT-AS1 regulated epithelial-mesenchymal transition in CCA. Taken together, these findings indicate that NNT-AS1/miR-142-5p/HMGA2 axis plays a crucial role in CCA progression and serve as potential biomarkers for diagnosis and therapeutic target in human CCA treatment.

Materials and methods

Patients and specimens

This study was approved by the research ethics committee of the First Affiliated Hospital of Zhengzhou University. A total of 98 primary CCA samples and matched normal tumor adjacent specimens used to analyze NNT-AS1 expression were obtained from patients who received surgical resection at the First Affiliated Hospital of Zhengzhou University, China (hereinafter referred to as the ZZU cohort). All patients were informed with consent and completed follow-up data records. Diagnoses and grading were confirmed by two experienced independent pathologists based on the 2010 CCA staging system of the AJCC. The clinico-pathological features of CCA ZZU cohort were listed in Table 1.
NNT-AS1 promotes cholangiocarcinoma progression

TCGA expression data sets analysis
The detailed procedures of TCGA analysis were described in our previous study [14, 15]. Briefly, we downloaded and analyzed gene expression profiles and corresponding clinical data of cholangiocarcinoma (referred to as the TCGA-CHOL cohort) from The Cancer Genome Atlas Project (TCGA; http://tcga-data.nci.nih.gov/).

Reverse transcription and real-time quantitative PCR (RT-qPCR)
Total RNA was extracted by Trizol (Takara, Japan), and then reversely transcribed to cDNA using Reverse Transcription Kits (Applied Biosystems, USA). Quantitative PCR was performed by SYBR PCR kits (Takara) on Real Time PCR Detection System (Bio-Rad). RNA concentration was measured by Nanodrop (Invitrogen, USA). Relative IncRNA levels were normalized against β-actin, and calculated using the 2^ΔΔCt methods. Each sample was analyzed in triplicate.

Cell lines and cell culture
The human CCA cell lines (RBE, HuCCT1, QBC939 and TFK1) and nonmalignant cholangiocyte cell line HIBEpic was obtained from the Cell Bank of Shanghai Institute of Cell Biology. All Cells were grown in RPMI 1640 medium (Invitrogen, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA) with 100 U/ml penicillin/streptomycin at 37°C in a humidified 5% CO₂ incubator. The cell lines used in present study were listed in Supplementary Figure 1.

Western blot
Total protein lysates was extracted and separated by SDS-PAGE, and then transferred to nitrocellulose membranes (Sigma, USA). Antibodies against N-cadherin, E-cadherin, MMP2 and MMP9 (Proteintech, China) were used, and actin was used as a loading control. After incubated with the secondary antibody (Proteintech, China), the membranes was detected and measured with the enhanced chemiluminescence system. The antibodies used in present study were listed in Supplementary Figure 1.

Knockdown or overexpression NNT-AS1 with shRNA or gene-encoded lentivirus
ShRNA used to silence NNT-AS1 and the lentiviral vector encoding the full NNT-AS1 sequence in present study were designed and provided by Hanbio company (Shanghai, China). Before transfection, cells (1 × 10⁶) were cultured until 80% confluence and transfected with same virus MOI into CCA cell lines. Then cells were cultured with 1.5 μg/mL puromycin (Invitrogen, USA) for 36 hours for selection. The transfection efficacy was assessed by RT-qPCR analysis.

Cell growth and colony formation assay
CCK-8 kit (Beyotime, China) was applied to investigate cell proliferation. 1 × 10⁴ cells were dispensed in a 96-well plate. At indicated time, 20 μL CCK-8 solution (5 mg/mL) was added into each well and dissolved in 150 μL dimethylsulphoxide (DMSO; USA). The 490 nm absorbance was measured by microplate reader (Molecular Devices, USA). For colony formation assay, treated cells (50 cells/well) were dispensed in a 24-well plate. Following 14 days culture, cells were fixed with 4% formaldehyde. Then colonies were stained with 0.5% crystal violet and calculated (defined as >50 cells).

5-ethyl-20-deoxyuridine (EdU) assay
Detailed EdU assay methods were provided in the supplemental data of the material and methods (Supplementary Figure 1).

Migration and invasion assays
Detailed migration and invasion assays methods were provided in the supplemental data of the material and methods (Supplementary Figure 1).

Luciferase reporter assays
WT or mutated 3’-UTR of NNT-AS1 or HMGA2 sequences were cloned and constructed into the pGL3-Luc reporter vector (Promega, USA). HEK293 was transfected with the WT or mutated luciferase reporter vectors, together with miR-142-5p mimics or negative control. Relative luciferase activity was analyzed using a Dual-Luciferase Reporter Assay System (Promega, USA) 48 h later.

In situ hybridization (ISH) and immunohistochemistry (IHC) assay
ISH and IHC staining were performed according to our previous study [16, 17]. In brief, TMA slices were washed and incubated with anti-NNT-AS1 oligodeoxy-nucleotide probes (RiboBio, China) at 37°C overnight. Next day, TMA were washed with 0.1% Tween-20 and re-stained by
NNT-AS1 promotes cholangiocarcinoma progression

DAPI. For IHC analysis, paraffin-embedded mice tumor sections were deparaffinized and immunostained with antibodies against Ki67, N-cadherin, E-cadherin, MMP2 and MMP9 (Proteintech, China).

In vivo tumor growth

Xenograft tumors model was established according to our previous study [18]. BALB/c nude mice (Vital River Laboratory, China) were used and grouped into (1) NNT-AS1 silencing group (implanted with NNT-AS1 stable knockdown CCA cell lines) or NNT-AS1 overexpression group (implanted with NNT-AS1 stable overexpression CCA cell lines) (2) Control group (implanted with negative control cells). 1 × 10^7 cells were implanted into the right axillary fossa of nude mice. Tumors were photographed with an IVIS® Lumina II system (Caliper Life Sciences, USA) every week, while tumor volumes and weights were recorded. Tumor volume was calculated by using the equation: length × width^2 × 1/2. All procedures were approved by the Experimental Animal Ethics Committee of The First Affiliated Hospital of Zhengzhou University.

Statistical analysis

All statistical analyses were conducted using SPSS version 23.0 software. Results were presented as mean ± SD of at least three independent experiments. The differences between groups were analyzed by Student’s t-test (two-tailed) or Chi-square test. Student’s t-test (two-tailed) and Mann-Whitney test were performed to analyze the in vitro and in vivo data. The Kaplan-Meier and log-rank test method was performed to determine survival rate. P values less than 0.05 were considered to be statistically significant.

Results

NNT-AS1 is upregulated in human CCA tissues and cell lines

Through TCGA database analysis, we identified dysregulated expression of NNT-AS1 in a myriad of cancer types (Figure 1A). The results also showed that NNT-AS1 was markedly overexpressed in CCA tissues compared with normal tissues in TCGA CHOL cohort (Figure 1B). To
NNT-AS1 promotes cholangiocarcinoma progression

**Figure 2.** High expression of NNT-AS1 is positively associated with clinical malignant and poor prognosis in CCA patients. A. Representative ISH staining of NNT-AS1 (left panel) and the quantification of NNT-AS1 ISH staining scores in CCA tissues and corresponding normal tissues (right panel). B. Representative pictures of NNT-AS1 expression with different staining scores in CCA tissues. C-E. Analysis the association between NNT-AS1 expression and metastasis, vascular invasion and histological differentiation. F, G. The overall survival and disease-free survival were analyzed by Kaplan-Meier analysis, according to NNT-AS1 expression levels. *P<0.05, **P<0.01, Mean ± SD, unpaired Student's t-test or Kaplan Meier analysis.

To further validate the expression pattern of NNT-AS1 in CCA, 30 pairs of CCA tissues and surrounding bile duct tissues were collected to determine the expression of NNT-AS1 by RT-qPCR and the results revealed the increased expression of NNT-AS1 in CCA tissues (Figure 1C and 1D). We next measured the expression levels of NNT-AS1 in human CCA cell lines. As shown in Figure 1E, NNT-AS1 expression was significantly higher in CCA cell lines (RBE, HuCCT1, QBC939 and TFK1) than that in control cell line HIBEpic.

High expression of NNT-AS1 is positively associated with clinical malignant and poor prognosis in CCA patients

We further performed in situ hybridization (ISH) analysis to explore the expression of NNT-AS1 in CCA tissues and non-tumor control tissues (Figure 2A and 2B). We found that NNT-AS1 expression was significantly higher in CCA tissues compared with that in paired normal bile duct tissues. Furthermore, high expression of NNT-AS1 was positively correlated with metastasis, vascular invasion and histological differentiation. The overall survival and disease-free survival were analyzed by Kaplan-Meier analysis, according to NNT-AS1 expression levels. *P<0.05, **P<0.01, Mean ± SD, unpaired Student's t-test or Kaplan Meier analysis.
NNT-AS1 promotes cholangiocarcinoma progression

Table 2. Univariate and multivariate analyses of overall survival of studied CCA patients

<table>
<thead>
<tr>
<th></th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Univariate analysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Age</td>
<td>1.223</td>
<td>0.546-1.365</td>
</tr>
<tr>
<td>Gender</td>
<td>0.774</td>
<td>0.546-1.365</td>
</tr>
<tr>
<td>Liver Cirrhosis</td>
<td>1.156</td>
<td>0.876-1.464</td>
</tr>
<tr>
<td>TNM stage</td>
<td>2.551</td>
<td>1.837-2.905</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>1.321</td>
<td>1.108-1.543</td>
</tr>
<tr>
<td>Intrahepatic metastasis</td>
<td>1.900</td>
<td>1.030-2.966</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td>2.006</td>
<td>1.199-3.378</td>
</tr>
<tr>
<td>Tumor multiplicity</td>
<td>1.352</td>
<td>1.238-1.659</td>
</tr>
<tr>
<td>HBsAg</td>
<td>1.307</td>
<td>1.102-1.683</td>
</tr>
<tr>
<td>NNT-AS1 expression</td>
<td>2.099</td>
<td>1.259-3.346</td>
</tr>
</tbody>
</table>

Univariate and multivariate analysis of disease-free survival in CCA patients (n=95)

<table>
<thead>
<tr>
<th></th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Age</td>
<td>1.009</td>
<td>0.599-1.958</td>
</tr>
<tr>
<td>Gender</td>
<td>0.885</td>
<td>0.477-1.600</td>
</tr>
<tr>
<td>Liver Cirrhosis</td>
<td>0.674</td>
<td>0.396-1.303</td>
</tr>
<tr>
<td>TNM stage</td>
<td>2.663</td>
<td>1.701-3.339</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>1.419</td>
<td>1.208-2.047</td>
</tr>
<tr>
<td>Intrahepatic metastasis</td>
<td>2.045</td>
<td>1.662-3.749</td>
</tr>
<tr>
<td>Vascular invasion</td>
<td>3.068</td>
<td>1.479-4.765</td>
</tr>
<tr>
<td>Tumor multiplicity</td>
<td>2.996</td>
<td>1.225-6.012</td>
</tr>
<tr>
<td>HBsAg</td>
<td>1.473</td>
<td>0.603-1.961</td>
</tr>
<tr>
<td>NNT-AS1 expression</td>
<td>2.108</td>
<td>1.561-2.594</td>
</tr>
</tbody>
</table>

Knockdown of NNT-AS1 suppresses cell proliferation of CCA both in vitro and in vivo

To explore the biological function of NNT-AS1 in CCA, we firstly determined the effect of NNT-AS1 silencing on cell proliferation through shRNA knockdown approach. NNT-AS1 knockdown efficiency was validated in TFK1 and QBC939 cells (Figure 3A and 3B). CCK-8 assay showed that cell growth of the NNT-AS1-silenced TFK1 or QBC939 cells was significantly inhibited compared with that in cells transfected with negative controls (Figure 2C and 2D). In parallel, EdU assay also demonstrated that knockdown of NNT-AS1 effectively inhibited the cell proliferation (Figure 2E and 2F).

To further evaluate the function of NNT-AS1 on CCA cell proliferation in vivo, TFK1 cells stably transfected with NC or shNNT-AS1-1 were inoculated into nude mice. Consistent with the in vitro findings, results showed that xenograft tumors grown from NNT-AS1-silenced cells had markedly less mean luciferase signal than that of control.
NNT-AS1 promotes cholangiocarcinoma progression

A. Relative expression of NNT-AS1

B. Relative expression of NNT-AS1

C. Relative OD 490 value

D. Relative OD 490 value

E. EDU, DAPI, Merge

F. Relative EdU positive cells (%)
NNT-AS1 promotes cholangiocarcinoma progression

Figure 3. Knockdown of NNT-AS1 suppresses cell proliferation of CCA both in vitro and in vivo. TFK1 or QBC939 cells were transfected with shRNA1/2/3 targeting NNT-AS1, respectively. A, B. The NNT-AS1 knockdown efficiency was determined by RT-qPCR. C, D. CCK-8 assay was performed to determine the viability of sh-NNT-AS1-1/2-transfected TFK1 or QBC939 cells at indicated time points. E, F. EdU staining assay was performed to determine the growth of sh-NNT-AS1-1/2-transfected TFK1 or QBC939 cells. TFK1 cells stably transfected with sh-NNT-AS1-1 or negative control (NC) were implanted into nude mice. Xenograft tumor was monitored for 5 weeks. G, H. Luciferase signal in the NC or sh-NNT-AS1-1 group was determined at indicated time points. I, J. Tumor growth and tumor volume were analyzed at indicated time points. Mice were euthanized and tumor tissues were extracted at week 5. Tumor weight was measured. Values are the mean ± SD (n=6/group). K, L. H&E and Ki67 IHC staining of xenograft tumors tissues from NC or sh-NNT-AS1-1 group. Mean ± SD, **P<0.01, unpaired Student’s t-test or one-way ANOVA followed by multiple t-test. Representative images and data are based on three independent experiments.
NNT-AS1 promotes cholangiocarcinoma progression

A. Relative expression of NNT-AS1

B. Relative expression of NNT-AS1

C. Comparative OD 490 value (Blank, NC, Lenti-NNT-AS1)

D. Relative OD 490 value (Blank, NC, Lenti-NNT-AS1)

E. Fluorescence images of EDU, DAPI, Merge (RBE, HuCCT1)

F. Relative Edu positive cells (%) (RBE, HuCCT1)
Figure 4. Overexpression of NNT-AS1 promotes cell proliferation of CCA both in vitro and in vivo. RBE or HuCCT1 cells were transfected with Lenti-NNT-AS1 or negative control (NC). A, B. NNT-AS1 expression in RBE or HuCCT1 cells was analyzed by RT-qPCR. C, D. CCK-8 assay was performed to assess the viability of RBE cells and HuCCT1 cells after NNT-AS1 overexpression. E, F. Edu staining assay was performed to determine the growth of RBE cells and HuCCT1 cells. RBE cells stably transfected with Lenti-NNT-AS1 or negative control (NC) were implanted into nude mice. Xenograft tumor was monitored for 5 weeks. G, H. Luciferase signal in the NC or Lenti-NNT-AS1 group was determined at indicated time points. I, J. Tumor growth and tumor volume were analyzed at indicated time points. Mice were euthanized and tumor tissues were extracted at week 5. Tumor weight was measured. Values are the mean ± SD (n=6/group). K, L. H&E and Ki67 IHC staining of xenograft tumors tissues from NC or Lenti-NNT-AS1 group. Mean ± SD. *P<0.05, **P<0.01, unpaired Student’s t-test or one-way ANNOVA followed by multiple t-test. Representative images and data are based on three independent experiments.
NNT-AS1 promotes cholangiocarcinoma progression

of the tumors developed from NC cells (Figure 3G and 3H). Correspondingly, tumor volume and weight were markedly decreased in the sh-NNT-AS1 group compared with that in control group (Figure 3I and 3J). In addition, comparison with that in tumor tissues resected from control group, sh-NNT-AS1 derived tumors showed significantly weaker proliferation marker ki-67 staining (Figure 3K and 3L). These results confirmed the pro-oncogenic role of NNT-AS1 in CCA tumorigenesis.

Overexpression of NNT-AS1 promotes cell proliferation of CCA both in vitro and in vivo

To further address the role of NNT-AS1 in CCA progression, we overexpressed NNT-AS1 in RBE and HuCCT1 cells with Lenti-NNT-AS1 transduction (Figure 4A and 4B). Functionally, we found that NNT-AS1 overexpression significantly enhanced the proliferative potential of RBE and HuCCT1 cells by CCK-8 assay and EdU assay (Figure 4C-F). Furthermore, we subcutaneously injected BALB/c nude mice with stably NNT-AS1 overexpression RBE cells. After 5 weeks, xenograft tumors grown from Lenti-NNT-AS1 cells showed dramatic increased mean luciferase signal than that in tumors developed from NC cells via ex vivo imaging analysis (Figure 4G and 4H). In addition, we observed that the tumor growth rate, tumor volume and tumor weight were markedly increased in Lenti-NNT-AS1 group compared to that in control group (Figure 4I and 4J). Moreover, tumors from Lenti-NNT-AS1 showed higher ki-67 expression than that in tumors from NC group (Figure 4K and 4L). These gain-of-function results combined with the loss-of-function data revealed that NNT-AS1 facilitated CCA growth.

NNT-AS1 promotes CCA cell invasion and migration via promoting EMT

Given that high expression of NNT-AS1 was associated with vascular invasion and progression in patients with CCA, we further evaluated the effect of NNT-AS1 knockdown or overexpression on CCA cell migration and invasion. Transwell assay revealed that knockdown of NNT-AS1 impeded the invasive ability of CCA cells (Figure 5A). In parallel, a corresponding suppressive effect on migration was also observed via wound-healing assay (Figure 5B). In contrast, invasion and migration abilities of CCA cells were enhanced by NNT-AS1 overexpression (Figure 5C and 5D).

To explore underlying mechanisms of NNT-AS1 involved in CCA metastasis. Gene set enrichment analysis (GSEA) of the CCA gene expression profile from TCGA database was conducted and results showed a significant correlation between NNT-AS1 expression and EMT (Figure 5E-G). We demonstrated that knockdown NNT-AS1 decreased the expression of N-cadherin, MMP2 and MMP9, and enhanced the expression of E-cadherin. Overexpression NNT-AS1 showed the opposite effect as shown by western blot results (Figure 5H). Furthermore, IHC analysis confirmed that tumor tissues from sh-NNT-AS1-1 group exhibited decreased expression of N-cadherin, MMP2 and MMP9, as well as increased expression of E-cadherin (Figure 5I). Collectively, these data suggested that repression of NNT-AS1 could suppress the migration and invasion of CCA cells, at least in part, by regulating the EMT.

NNT-AS1 directly interacts with miR-142-5p as miRNA sponge

To explore how NNT-AS1 regulates CCA progression and metastasis, we performed bioinformatics analysis to search for the potential targets of NNT-AS1. As shown in Figure 6A, miR-142-5p was predicted to have the putative binding sites with NNT-AS1. Pearson correlation analysis showed that NNT-AS1 expression was negatively associated with miR-142-5p expression (Figure 6B). We also found that the expression of miR-142-5p in CCA tissues was markedly lower than that in non-tumor control tissues in TCGA-CHOL cohort (Figure 6C). Consistently, the results showed that CCA cell lines (RBE, HuCCT1, QBC939 and TFK1) had significantly lower miR-142-5p expression than that in control cell line HIBEpic (Figure 6D). Previous study has shown that multiple IncRNAs are known to function as competing endogenous RNA (ceRNAs) for specific miRNAs [19]. While overexpression NNT-AS1 significantly inhibited miR-142-5p expression (Figure 6E), NNT-AS1 knockdown increased miR-142-5p expression (Figure 6F). Luciferase reporter assay showed that miR-142-5p mimics significantly inhibited the luciferase activity in HEK293 cells transfected with reporter vector containing wild type NNT-AS1, but not with mutant NNT-AS1 (Figure 6G).
NNT-AS1 promotes cholangiocarcinoma progression

A

B

C

D

E

F

G

Gotzmann epithelial to mesenchymal transition up

Jechlinger epithelial to mesenchymal transition up

Anastassioucancer mesenchymal transition signature
NNT-AS1 promotes cholangiocarcinoma progression

Figure 5. NNT-AS1 promotes CCA cell invasion and migration via promoting EMT. A. TFK1 or QBC939 cells were transfected with shNNT-AS1-1 or negative control (NC). Transwell assay was performed to evaluate the cell invasion. B. TFK cells were transfected with shNNT-AS1-1 or NC. Wound-healing assay was conducted to evaluate the cell migration capability. C. RBE or HuCCT1 cells were transfected with Lenti-NNT-AS1-1 or NC. Transwell assay was performed to evaluate the cell invasion. D. RBE cells were transfected with Lenti-NNT-AS1-1 or NC. Wound-healing assay was conducted to evaluate the cell migration capability. E-G. Gene Set Enrichment Analysis indicated a significant correlation between NNT-AS1 expression and EMT. H. Western blot analysis of E-cadherin, N-cadherin, MMP2 and MMP9 in TFK1 cells transfected with shNNT-AS1-1 or NC, or in RBE cells transfected with Lenti-NNT-AS1 or NC. I. IHC staining analysis of E-cadherin, N-cadherin, MMP2 and MMP9 in tumor tissues from NNT-AS1 silencing or overexpression group. Scale bar, 100 μm. Mean ± SD, *P<0.05, **P<0.01, unpaired Student’s t-test. Representative images and data are based on three independent experiments.
To further validate the interaction between miR-142-5p and NNT-AS1, RBE or HuCCT1 cells were transfected with miR-142-5p mimics or mock control, with/without NNT-AS1 overexpression vector. Cell proliferation assessed by CCK-8, colony formation and transwell assays showed that while overexpression of miR-142-5p suppressed cell proliferation, colony formation and cell invasion of RBE or HuCCT1 cells, overexpression of NNT-AS1 partially reversed the suppressive effect of miR-142-5p in these cells (Figure 7A-C). These results confirmed the...
interaction between miR-142-5p and NNT-AS1 cooperatively regulated CCA cells proliferation and invasion.

**MiR-142-5p negatively regulates High Mobility Group AT-Hook 2 (HMGA2) expression by targeting 3'-UTR of HMGA2.**

To further investigate the potential target of miR-142-5p, we searched for miR-142-5p targets by online bioinformatics tool TargetScan. Intriguingly, HMGA2 was identified to have putative binding sites of miR-142-5p (**Figure 8A**). Consistently, the expression of HMGA2 was significantly negative-associated with the expression of miR-142-5p (**Figure 8B**). In addition, dual luciferase reporter assay showed that miR-142-5p mimics inhibited luciferase activity in HEK293 cells transfected with the reporter plasmid containing WT HMGA2 3'-UTR, while no significant suppression was found in HEK293 cells transfected with the reporter plasmid containing the mutant HMGA2 3'-UTR (**Figure 8C**). Moreover, HMGA2 mRNA and protein levels were dramatically decreased by ectopic miR-142-5p overexpression and increased...
NNT-AS1 promotes cholangiocarcinoma progression

**Figure 8.** MiR-142-5p negatively regulates High Mobility Group AT-Hook 2 (HMGA2) expression by targeting 3'-UTR of HMGA2. A. Graphical representation of the potential binding sites between miR-142-5p and HMGA2. B. Correlation between HMGA2 and miR-142-5p was analyzed by Pearson's correlation curve. C. Luciferase reporter assay was performed and the relative luciferase activity was tested after cotransfection with HMGA2 wide type, HMGA2 mutant type and miR-142-5p mutant. D, E. RBE or HuCCT1 cells were transfected with miR-142-5p mimics, inhibitor or negative controls. The mRNA and protein expression levels of HMGA2 were analyzed by RT-qPCR and western blot. F. Western blot analysis of E-cadherin, N-cadherin, MMP2 and MMP9 in HuCCT1 cells treated with siRNA targeting HMGA2 or negative group. Mean ± SD, *P<0.05 and **P<0.01, unpaired Student’s t-test. Representative images and data are based on three independent experiments.

when transfected with miR-142-5p inhibitor in RBE or HuCCT1 cells (**Figure 8D, 8E**). We also demonstrated that knockdown HMGA2 decreased the EMT-related N-cadherin, MMP2, and MMP9 expression while enhanced E-cadherin expression (**Figure 8F**). Together, these data validated that miR-142-5p directly regulated HMGA2 expression by targeting the 3'-UTR of HMGA2.

**Discussion**

Cholangiocarcinoma is a highly malignant biliary tumor with poor outcome. It has been well proven that lncRNAs can influence various tumorigenesis processes by multiple mechanisms [6]. In the past decades, promising evidence has shown that lncRNAs are important factors in cancer and dysregulation of lncRNAs...
NNT-AS1 promotes cholangiocarcinoma progression

contributed to potential pathophysiological in various human cancer types [20]. Thus, the identification of IncRNAs associated with CCA progression may provide in-depth understanding on the progression of CCA.

In the current study, we revealed that IncRNA NNT-AS1 was dramatically upregulated in CCA and high NNT-AS1 expression was associated with differentiation, depth of invasion, TNM stage and worse prognosis. Multivariate analyses indicated that NNT-AS1 could be a novel and effective biomarker for risk prognostic. Consistent with our study, several studies reported that upregulated NNT-AS1 could be severed as a dependent negative prognostic factor for cancer. For example, NNT-AS1 was found with enhanced expression in human osteosarcoma, cervical, colorectal, breast, liver and ovarian cancer. Additional, up-regulated NNT-AS1 was correlated with clinical malignancies and poor prognosis of these malignancies [7, 10-13, 21-25]. Together, our findings suggest that NNT-AS1 overexpression represents an excellent biomarker of poor prognosis in CCA.

Next, we explored the biological function of NNT-AS1 in CCA. We found that NNT-AS1 knock-down led to significant inhibition of CCA cell proliferation, migration and invasion, while NNT-AS1 overexpression promoted cell invasion and cell viability in vitro and in vivo. These findings indicate that NNT-AS1 plays a crucial role in the CCA progression, stimulating novel therapeutic directions considering NNT-AS1 as a potential therapeutic target in CCA. In agreement with our results, Wang et al. reported that NNT-AS1 depletion inhibited cell proliferation and colony formation in colorectal cancer [13]. Hua et al. indicated that NNT-AS1 enhanced cell proliferation and invasion through activating Wnt/β-catenin pathway in cervical cancer [10]. Li et al. showed that NNT-AS1 accelerated cell migration and invasion in CCA and functioned as a sponge to bind to miR-142-3p [23]. Intriguingly, we also demonstrated that NNT-AS1 functioned as a ceRNA to bind to miR-142-5p. MiR-142-5p expression was negatively correlated with NNT-AS1 expression in CCA. These data indicate that NNT-AS1 might act as an oncogene in the development of CCA, also could be considered as a potential therapeutic target. However, the underlying mechanism of NNT-AS1-regulated CCA tumorigenicity remains to be elucidated.

It is widely accepted that EMT is involved in tumor metastasis and the characteristics of EMT include the inhibited E-cadherin, increased N-cadherin and Vimentin expression as well as enhanced MMP members protein [26, 27]. A growing body of evidence revealed that LncRNA played a crucial role in the incidence of metastasis through regulating EMT [28, 29]. Zhao et al. observed that IncRNA TUG1 promoted Pancreatic carcinoma progression through enhancing EMT phenotype [30]. Yan et al. demonstrated that upregulated SNHG6 was related with invasion and promoted gastric cancer cell EMT [31]. In addition, overexpressed IncRNA PincRNA-1 could promote metastasis through inducing EMT in hepatocellular carcinoma [32]. In accordance with above previous reports, we found significant changed EMT markers after NNT-AS1 silencing or overexpression. Furthermore, we demonstrated that miR-142-5p directly targeting HMGA2, which was reported to induce EMT in human hepatocellular carcinoma [33]. Consistently, the GSEA showed high NNT-AS1 expression was markedly correlated with gene signatures of EMT. These results indicate that NNT-AS1/miR-142-5p/HMGA2 might promote the potential of CCA metastasis partly by enhancing EMT.

Although our study did not provide direct evidence whether the changes in EMT were required for the regulation of CCA cell proliferation and metastasis by NNT-AS1, numerous previous studies have implicated EMT process in the regulation of cell proliferation and metastasis. In this context, it is reasonable for us to conclude that NNT-AS1 promotes CCA cell metastasis via NNT-AS1 mediated regulation of EMT. Further investigation for NNT-AS1 relative to CCA metastasis is needed.

Conclusion

In summary, these findings suggest the potential prognostic and therapeutic value of NNT-AS1/miR-142-5p/HMGA2 axis in CCA patients. Although there is still a long way to go before the advent of IncRNA-based tumor therapy, our present study will undoubtedly enhance our knowledge of how NNT-AS1/miR-142-5p/HMGA2 functions in CCA, allowing us to better understand the pathogenesis and development of CCA.

Acknowledgements

This study was sponsored by grants from National S&T Major Project of China (2018ZX10-
NNT-AS1 promotes cholangiocarcinoma progression


NNT-AS1 promotes cholangiocarcinoma progression

Ren Z, Sun R, Cui G. LDHA is a direct target of miR-30d-5p and contributes to aggressive progression of gallbladder carcinoma. Mol Carcinog 2018; 57: 772-783.


Supplementary Figure 1. Original western images for all relevant western blots.